E-Therapeutics plc (ETX)
XSTU
Real-time Data
06:00 AM
Day's Range
8.2852 wk Range
4.41Overview - ETX - E-Therapeutics plc
Key Statistics
Valuation
Enterprise Value
1.78B
P/E (Trailing)
‪4.09‬
Price / Sales (TTM)
‪3.39‬
EV / EBITDA
‪7.04‬
Profitability
Profit Margin
‪51.08%‬
Operating Margin
‪70.29%‬
Return on Assets
‪16.52%‬
Return on Equity
‪26.52%‬
Ownership
Shares Outstanding
199.53M
Price stats
50-Day Avg
‪5.53‬
200-Day Avg
‪5.03‬
Dividends
Frequency
Annual
Peers - ETX - E-Therapeutics plc
Peer Comparison
Compared with companies in Oil & Gas E&P listed on XSTU.
- ETXXSTUE-Therapeutics plc1.95BMarket Cap+39.26%52-week change4.12P/E (Trailing)‪51.08%‬Profit Margin
- 6D40XSTUDelek Group Ltd. Unsponsored ADR39.58BMarket Cap+22.57%52-week change65.45P/E (Trailing)‪84.06%‬Profit Margin
- NVALXSTUPTT Exploration and Production Public Company Limited15.40BMarket Cap+24.87%52-week change0.25P/E (Trailing)‪61.93%‬Profit Margin
- XE3XSTUIthaca Energy plc5.21BMarket Cap+20.08%52-week change24.25P/E (Trailing)‪8.17%‬Profit Margin
- PXKXSTUPeyto Exploration & Development Corp.3.18BMarket Cap+25.98%52-week change10.37P/E (Trailing)‪40.24%‬Profit Margin
- NK1XSTUDNO ASA1.56BMarket Cap+27.33%52-week change23.68P/E (Trailing)‪4.95%‬Profit Margin
- AS4XSTUCorticeira Amorim, S.G.P.S., S.A.845.88MMarket Cap-10.12%52-week change11.57P/E (Trailing)‪54.63%‬Profit Margin
Profile Summary - ETX - E-Therapeutics plc
About
E-Therapeutics plc is a biotechnology company specializing in the integration of computational biology and RNA interference (RNAi) technologies to advance drug discovery. Its core focus lies in developing innovative RNAi medicines, leveraging proprietary platforms such as HepNet™, a hepatocyte-centric computational…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
